StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital assumed coverage on shares of InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 1.5 %

NSPR stock opened at $2.72 on Tuesday. The firm has a market cap of $70.94 million, a PE ratio of -3.63 and a beta of 0.99. The stock has a 50-day moving average price of $2.80 and a 200-day moving average price of $2.72. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42.

InspireMD (NYSE:NSPR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The firm had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the prior year, the business earned ($0.15) EPS. On average, analysts forecast that InspireMD will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC acquired a new position in InspireMD, Inc. (NYSE:NSPR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.